Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis
Journal of Biological Chemistry · 2024-06 · 300 (6) · 107300
DOI: 10.1016/j.jbc.2024.107300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024-06. Verfasst von Jessica F Calver und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Nottingham, Nottingham, United Kingdom; Stevenage Bioscience Catalyst, Galecto Biotech AB, Stevenage, United Kingdo…. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Galectin 3, Fibroblasts, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust, Galecto.
Abstract (Originalsprache)
Integrin-mediated activation of the profibrotic mediator transforming growth factor-β1 (TGF-β1), plays a critical role in idiopathic pulmonary fibrosis (IPF) pathogenesis. Galectin-3 is believed to contribute to the pathological wound healing seen in IPF, although its mechanism of action is not precisely defined. We hypothesized that galectin-3 potentiates TGF-β1 activation and/or signaling in the lung to promote fibrogenesis. We show that galectin-3 induces TGF-β1 activation in human lung fibroblasts (HLFs) and specifically that extracellular galectin-3 promotes oleoyl-L-α-lysophosphatidic acid sodium salt-induced integrin-mediated TGF-β1 activation. Surface plasmon resonance analysis confirmed that galectin-3 binds to αv integrins, αvβ1, αvβ5, and αvβ6, and to the TGFβRII subunit in a glycosylation-dependent manner. This binding is heterogeneous and not a 1:1 binding stoichiometry. Binding interactions were blocked by small molecule inhibitors of galectin-3, which target the carbohydrate recognition domain. Galectin-3 binding to β1 integrin was validated in vitro by coimmunoprecipitation in HLFs. Proximity ligation assays indicated that galectin-3 and β1 integrin colocalize closely (≤40 nm) on the cell surface and that colocalization is increased by TGF-β1 treatment and blocked by galectin-3 inhibitors. In the absence of TGF-β1 stimulation, colocalization was detectable only in HLFs from IPF patients, suggesting the proteins are inherently more closely associated in the disease state. Galectin-3 inhibitor treatment of precision cut lung slices from IPF patients' reduced Col1a1, TIMP1, and hyaluronan secretion to a similar degree as TGF-β type I receptor inhibitor. These data suggest that galectin-3 promotes TGF-β1 signaling and may induce fibrogenesis by interacting directly with components of the TGF-β1 signaling cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Nottingham, Nottingham, United Kingdom; Stevenage Bioscience Catalyst, Galecto Biotech AB, Stevenage, United Kingdom.
- School of Medicine, University of Nottingham, Nottingham, United Kingdom; Roche Products Limited, Welwyn Garden City, Hertfordshire, United Kingdom.
- Research Complex at Harwell, Rutherford Appleton Laboratory, Didcot, Oxfordshire, United Kingdom.
- Research Complex at Harwell, Rutherford Appleton Laboratory, Didcot, Oxfordshire, United Kingdom; School of Biosciences, University of Nottingham, Loughborough, Leicestershire, United Kingdom; Membrane Protein Laborator…
- Institute for Lung Health, NIHR Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom; Leicester Institute for Structural and Chemical Biology, Henry Wellcome Building, Universi…
- Galecto Biotech AB, Sahlgrenska Science Park, Gothenburg, Sweden.
Förderung
- Medical Research Council
- Wellcome Trust
- Galecto
- BBSRC
- University of Leicester
Zitieren
APA
Calver, J. F., Parmar, N. R., Harris, G., Lithgo, R. M., Stylianou, P., Zetterberg, F. R., Gooptu, B., Mackinnon, A. C., Carr, S. B., Borthwick, L. A., Scott, D. J., Stewart, I. D., Slack, R. J., Jenkins, R. G., & John, A. E. (2024). Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis. Journal of Biological Chemistry, 300(6), 107300. https://doi.org/10.1016/j.jbc.2024.107300
Vancouver
Calver JF, Parmar NR, Harris G, Lithgo RM, Stylianou P, Zetterberg FR, et al. Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis. Journal of Biological Chemistry. 2024;300(6):107300. doi:10.1016/j.jbc.2024.107300
BibTeX
@article{Calver2024,
author = {Calver, Jessica F and Parmar, Nimesh R and Harris, Gemma and Lithgo, Ryan M and Stylianou, Panayiota and Zetterberg, Fredrik R and Gooptu, Bibek and Mackinnon, Alison C and Carr, Stephen B and Borthwick, Lee A and Scott, David J and Stewart, Iain D and Slack, Robert J and Jenkins, R Gisli and John, Alison E},
title = {Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis},
journal = {Journal of Biological Chemistry},
year = {2024},
volume = {300},
number = {6},
pages = {107300},
doi = {10.1016/j.jbc.2024.107300}
}
EUVIMED